MOLECULAR DIAGNOSIS OF THE AVEN GENE AS A PROGNOS-TIC FACTOR IN BREAST CANCER PATIENTS

Authors

  • M. MOAWAD Department of Surgical Pathology, National Cancer Institute, Cairo University, Egypt
  • E. A. MOHAMED Biotechnology and Genetic Engineering Research Unit, Deanship of Scientific Research, Taif University, Kingdom of Saudi Arabia Department of Genetics, College of Agriculture, Cairo University, Cairo, Egypt
  • GHADA M. NASR Department of Molecular Diagnostics, Genetic Engineering & Biotechnology Research Institute, Sadat City University, Egypt
  • A. H. H. EZZAT Department of Surgical Oncology, National Cancer Institute, Cairo University, Egypt

Abstract

In the present study, we investigated the possible role of Aven gene and its expression at the transcription level detected by RT-PCR technique as a prognostic factor in breast cancer to confirm the prognosis assessed by the immunohisto-chemical analysis of Vegf and Ki67 genes, and ER, PR status.
The present study was performed on 40 diagnosed female breast cancer patients and 10 cases benign breast tissues. The fresh tumor tissues were divided into two fragments for histological, immuno-histological analysis and for the RT-PCR analysis.
In this study, we evaluated a conventional RT-PCR assay for Aven gene as a detection marker of 40 IDC patients. The findings were analyzed to assess the prognostic significance of Aven gene expression-detection in the breast tissues in association with the other known prognostic factors. Statistically significant association was found between positive Aven gene expression in the IDC and well established prognostic parameters; namely, Ki67, Vegf and hormonal status (P value <0.0001).
In breast cancer, Aven gene is considered responsible for circulating tumor tissues and its expression might constitute a biologically active subset of breast cancer patients with high tumor burden and bad prognosis. As the expression of Aven gene is easily determined by conventional RT-PCR, it may be useful marker to predict prognosis of breast cancer.

References

Bancroft, J. D. and M. Gamble (2002). Theory and Practice of Histological techniques, Fifth Edition; Elserviser Science Limited, 689-691.

Chau, B. N., E. H. Cheng, D. A. Kerr and J. M. Hardwick (2000). Aven a novel inhibitor of caspase activation binds Bcl-xL and Apaf-1. Mol. Cell, 6: 31-40.

El-Bolkainy, M., A. Noh, T. El-Bolkainy and M. O. Badawy (2013). Pathology of Cancer, 4th Edition. Medical bock library, Cairo, Egypt, 298-299.

Eissa, S. and S. Shoman (1998). Markers of invasion and metastasis and markers of tumor proliferation and apoptosis in: Tumors markers. Chapman and Hall, Lippincott-Raven Publisher Inc., London, UK, p. 131-153.

Everitt, B. and G. Dunn (1998). Statistical analysis of medical data new developments, US Oxford University press Inc., New York.

Hsu, S. M., L. Rsine and H. Fanger (2000). The use of avidin biotin peroxidase techniques complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-581.

Jeffrey, S. R., P. L. Gerald, S. James, C. Edwin, A. Mark, W. Nick, S. Fraser, N. H. Gabriel and P. Lajos (2003). Breast cancer biomarkers and molecular medicine. Expert Rev. Mol. Diagn., 3: 573-585.

Konecny, E., G. Meng and M. Untch (2004). Association between Her-2/neu and Vascular Endothelial Growth Factor expression predicts clinical outcome in primary breast cancer patients. Clin. Cancer Res., 10: 1706-1716.

Kutuk, O., S. G. Temel, S. Tolunay and H. Basaga (2010). Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL. Eur. J. Cancer, 46: 2494-2505.

Lee, S. and M. Rosen (2002). Clinical Experience With Angiogenesis Signaling Inhibitors: Focus on Vascular Endothelial Growth Factor (VEGF) Blockers. Cancer Control March/April, 9, No. 2, Supplement.

Omar, S., G. Contesso and H. Khaled (2010). Breast Cancer 3rd Edition, Publ. By Association Medical Franco Egyptienne, p. 33-87.

Ouzounova, M., T. Vuong, P. B. Ancey, M. Ferrand, G. Durand, F. Le-Calvez Kelm, C. Croce, C. Matar, Z. Herceg and H. Hernandez-Vargas (2013). Micro RNA 30 familly regulates non all atchments growth of breast cancer cells. BMC Genomics, Feb. 28; 14:139. doi: 10.1186/1471-2164-14-139.

Ozgur, K. A., G. M. Sehime, T. Sahsine and B. Huveyda (2010). Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL. European J. Cancer, 46: 2494-2505.

Park, S. S., Y. A. Kim, J. E. Kim, Y. C. Kim and S. W. Kim (2005). Caveolin-1 is down- regulated and inversely correlated with HER2 and EGFR exepression status in invasive ductal carcinoma of the breast. Histopatology, 47: 625-630.

Paydas, S., K. Tanriverdi, S. Yavuz, U. Disel, B. Sahin and R. Burgut (2003). Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Annals Oncol, 14: 1045-1050.

Ross, J. S. and J. A. Fletcher (2000). The HER2/neu oncogene in breast cancer: prognostic factor, predictor factor and target for therapy. Stem Cell, 16: 413-428.

WHO report (2013). Relative Frequency of Major Cancers in Men and Women Worldwide 2012.

Yerushalmi, R., S. Woods and M. Ravdin (2010). Ki67 in breast cancer: Prognostic and Predictive Potential. Lancet Oncol, 11: 174-183.

Downloads

Published

2016-01-12

Issue

Vol. 44 No. 1 (2015)

Section

Articles

Most read articles by the same author(s)

<< < 1 2